Stock Market & Financial Investment News

News Breaks January 21, 2013 19:26 EDT JNJ J&J's Cordis announces two-year results from STROLL trial Cordis, a unit of Johnson & Johnson, announced the presentation of the two-year STROLL study results. In the study, the average lesion length was 77 mm, 23.6% of patients presented with total occlusions and 47% of patients were diabetic. Freedom from clinically driven target lesion revascularization at two years was 80.3%. The 24-month primary patency rate for the S.M.A.R.T. Stent was 74.9% by Kaplan Meier estimate. The primary duplex patency rate was 83.5%. There were no major adverse events at 30 days after the initial index procedure, Cordis added. There was also a low rate of stent fractures noted at 12 months with no additional fractures reported out to 24 months, the company said. All stent fractures were Type I, least severe, and there were no incidents of more severe stent fractures. STROLL is a multicenter, non-randomized, single-arm, prospective trial comparing the safety and efficacy of the S.M.A.R.T. Stent with a previously published objective performance goal. News For JNJ From The Last 14 Days Check below for free stories on JNJ the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 06:19 EDT JNJ J&J to end sales of of metal-on-metal hip replacements, Bloomberg reports Subscribe for More Information May 15, 2013 16:51 EDT JNJ FDA approves Simponi to treat ulcerative colitis Subscribe for More Information May 10, 2013 11:48 EDT JNJ Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 06:16 EDT JNJ Obesity surgery booming in India, Bloomberg reports Subscribe for More Information May 9, 2013 17:09 EDT JNJ Johnson & Johnson deal to settle sales practices probe stalls, WSJ reports Johnson & Johnson's $2.2B settlement with the Justice Department related to its promotion of certain drugs is on hold as the company is looking to avoid language in the agreement that could make it vulnerable to private lawsuits, reports The Wall Street Journal, citing people familiar with the talks. Reference Link 09:51 EDT JNJ J&J unit says first patient enrolled in reMARQable study Subscribe for More Information May 8, 2013 07:38 EDT JNJ BofA/Merrill's medical tech analyst hold an analyst/industry conference call Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.